TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics
Cryoport, Inc. (NASDAQ: CYRX) and TMRW Life Sciences have announced a strategic partnership to provide fertility clinics with complete solutions for secure specimen management and transport. This collaboration aims to address the growing demand for offsite storage of frozen specimens in fertility clinics.
The partnership combines TMRW's FDA-cleared automated specimen management and storage platform with Cryoport Systems' expertise in biologistics and transport. Both companies are ISO-certified, ensuring high-quality standards. TMRW offers HIPAA-compliant, military-grade data security with SOC II and HITRUST certifications, while Cryoport brings over a decade of experience in reproductive medicine biologistics and its Cryoportal® Logistics Management Platform.
This collaboration is expected to provide fertility clinics with comprehensive, trusted solutions for managing their growing specimen inventories with enhanced safety and reliability.
Cryoport, Inc. (NASDAQ: CYRX) e TMRW Life Sciences hanno annunciato una partnership strategica per fornire alle cliniche di fertilità soluzioni complete per la gestione e il trasporto sicuro dei campioni. Questa collaborazione mira a soddisfare la crescente domanda di storage offsite dei campioni congelati nelle cliniche di fertilità.
La partnership combina la piattaforma di gestione e stoccaggio automatizzato dei campioni approvata dalla FDA di TMRW con l'expertise di Cryoport Systems nella biologistica e nel trasporto. Entrambe le aziende sono certificate ISO, garantendo standard di alta qualità. TMRW offre sicurezza dei dati conforme a HIPAA, di grado militare, con certificazioni SOC II e HITRUST, mentre Cryoport vanta oltre un decennio di esperienza nella biologistica per la medicina riproduttiva e la sua piattaforma di gestione logistica Cryoportal®.
Questa collaborazione è destinata a fornire alle cliniche di fertilità soluzioni complete e affidabili per la gestione delle loro crescenti scorte di campioni, con una maggiore sicurezza e affidabilità.
Cryoport, Inc. (NASDAQ: CYRX) y TMRW Life Sciences han anunciado una asociación estratégica para proporcionar a las clínicas de fertilidad soluciones completas para la gestión y el transporte seguro de muestras. Esta colaboración tiene como objetivo abordar la creciente demanda de almacenamiento fuera del sitio de muestras congeladas en clínicas de fertilidad.
La asociación combina la plataforma de gestión y almacenamiento automatizado de muestras de TMRW, aprobada por la FDA, con la experiencia de Cryoport Systems en biología y transporte. Ambas empresas están certificadas por ISO, garantizando altos estándares de calidad. TMRW ofrece seguridad de datos conforme a HIPAA, de grado militar, con certificaciones SOC II y HITRUST, mientras que Cryoport aporta más de una década de experiencia en biología de medicina reproductiva y su plataforma de gestión logística Cryoportal®.
Se espera que esta colaboración proporcione a las clínicas de fertilidad soluciones integrales y confiables para gestionar sus crecientes inventarios de muestras, con mayor seguridad y fiabilidad.
Cryoport, Inc. (NASDAQ: CYRX)와 TMRW Life Sciences는 생식 클리닉에 안전한 샘플 관리 및 운송을 위한 완벽한 솔루션을 제공하는 전략적 파트너십을 발표했습니다. 이 협력은 생식 클리닉 내에서 냉동 샘플의 오프사이트 저장소에 대한 수요 증가를 해결하는 것을 목표로 합니다.
이 파트너십은 TMRW의 FDA 승인 자동 샘플 관리 및 저장 플랫폼과 Cryoport Systems의 생물 물류 및 운송 전문성을 결합합니다. 두 회사는 ISO 인증을 보유하고 있어 높은 품질 기준을 보장합니다. TMRW는 HIPAA 준수, 군사 등급 데이터 보안을 제공하며 SOC II 및 HITRUST 인증을 보유하고 있는 반면, Cryoport는 생식 의학 생물 물류 분야에서 10년 이상의 경험과 Cryoportal® 물류 관리 플랫폼을 제공합니다.
이번 협업은 생식 클리닉이 증가하는 샘플 재고를 보다 안전하고 신뢰할 수 있는 방식으로 관리할 수 있는 포괄적이고 신뢰할 수 있는 솔루션을 제공할 것으로 기대됩니다.
Cryoport, Inc. (NASDAQ: CYRX) et TMRW Life Sciences ont annoncé un partenariat stratégique pour fournir aux cliniques de fertilité des solutions complètes pour la gestion et le transport sécurisé des échantillons. Cette collaboration vise à répondre à la demande croissante de stockage hors site d'échantillons congelés dans les cliniques de fertilité.
Le partenariat associe la plateforme de gestion et de stockage automatisé des échantillons de TMRW, approuvée par la FDA, à l'expertise de Cryoport Systems en biologistique et en transport. Les deux entreprises sont certifiées ISO, garantissant des normes de qualité élevées. TMRW propose une sécurité des données conforme à la HIPAA, de niveau militaire, avec des certifications SOC II et HITRUST, tandis que Cryoport apporte plus d'une décennie d'expérience en biologistique pour la médecine reproductive et sa plateforme de gestion logistique Cryoportal®.
Cette collaboration devrait offrir aux cliniques de fertilité des solutions complètes et fiables pour gérer leurs croissantes inventaires d'échantillons avec une sécurité et une fiabilité accrues.
Cryoport, Inc. (NASDAQ: CYRX) und TMRW Life Sciences haben eine strategische Partnerschaft angekündigt, um Fertilitätskliniken vollständige Lösungen für die sichere Verwaltung und den Transport von Proben anzubieten. Diese Zusammenarbeit zielt darauf ab, der wachsenden Nachfrage nach Außenlagerung von gefrorenen Proben in Fertilitätskliniken gerecht zu werden.
Die Partnerschaft kombiniert die von der FDA zugelassene automatisierte Probenverwaltungs- und Lagerplattform von TMRW mit der Expertise von Cryoport Systems in der Biologistik und im Transport. Beide Unternehmen sind ISO-zertifiziert, was hohe Qualitätsstandards gewährleistet. TMRW bietet HIPAA-konforme, militärgradige Datensicherheit mit SOC II- und HITRUST-Zertifizierungen, während Cryoport auf über ein Jahrzehnt Erfahrung in der Biologistik der Reproduktionsmedizin und seine Cryoportal®-Logistikmanagement-Plattform zurückblickt.
Diese Zusammenarbeit soll Fertilitätskliniken umfassende, vertrauenswürdige Lösungen für die Verwaltung ihrer wachsenden Probenbestände mit erhöhter Sicherheit und Zuverlässigkeit bieten.
- Strategic partnership between two industry leaders in fertility specimen management and biologistics
- Addresses growing demand for offsite storage of frozen specimens in fertility clinics
- Combines TMRW's FDA-cleared automated specimen management platform with Cryoport's expertise in biologistics
- Both companies are ISO-certified, ensuring high-quality standards
- Offers enhanced security and reliability for specimen management and transport
- None.
Insights
This strategic partnership between TMRW Life Sciences and Cryoport Systems represents a significant advancement in the fertility industry's specimen management and logistics capabilities. The collaboration combines TMRW's FDA-cleared automated specimen management and storage platform with Cryoport's expertise in temperature-controlled logistics.
Key benefits include:
- Enhanced security and reliability for offsite storage of frozen eggs, embryos and sperm
- Improved biologistics and transport between TMRW Biorepositories and fertility clinics
- Comprehensive solutions for managing growing specimen inventories
- Integration of advanced technologies for specimen tracking and monitoring
The partnership addresses the increasing demand for secure offsite storage solutions in the fertility sector. By combining their ISO-certified processes and advanced technologies, TMRW and Cryoport are setting a new standard for specimen management and transport in reproductive medicine.
This collaboration could potentially increase Cryoport's market share in the reproductive medicine biologistics sector, which may positively impact the company's revenue streams. However, the full financial impact will depend on the adoption rate of this integrated solution by fertility clinics and the terms of the partnership agreement.
This strategic partnership has several positive implications for Cryoport (NASDAQ: CYRX):
- Market Expansion: By partnering with TMRW Life Sciences, Cryoport gains access to a broader customer base in the growing fertility market, potentially increasing its revenue and market share.
- Service Differentiation: The collaboration allows Cryoport to offer a more comprehensive and integrated solution, combining its logistics expertise with TMRW's storage technology. This could lead to increased customer retention and higher-value contracts.
- Technological Synergy: Integrating Cryoport's Cryoportal® Logistics Management Platform with TMRW's ivfOS software creates a unique, end-to-end digital solution that could be a significant competitive advantage.
- Risk Mitigation: The partnership with an FDA-cleared and highly certified company like TMRW may help Cryoport mitigate operational and regulatory risks in the sensitive field of reproductive medicine.
While specific financial terms are not disclosed, this partnership aligns with Cryoport's strategy to expand its presence in the reproductive medicine sector. Investors should monitor for potential revenue growth and margin improvements in Cryoport's future financial reports as a result of this collaboration.
Two ISO-Certified Industry Leaders Collaborate to Provide Fertility Clinics with Complete, Trusted
Solutions for Secure IVF Specimen Management and Transport
As the demand for offsite storage of frozen specimens for fertility clinics grows, this partnership addresses the increasing need for reliable, efficient, and secure shipping solutions. Under this partnership, the biologistics and transport of specimens between the TMRW Biorepositories and fertility clinics will be handled by Cryoport Systems, combining two industry-leading companies committed to delivering the gold standard in fertility specimen management and biologistics. Together, they offer fertility clinics comprehensive, trusted solutions to manage their growing specimen inventories with unparalleled safety and reliability.
"This partnership with Cryoport reflects our dedication to providing patients and clinics with the highest standard of care," said Louis Villalba, TMRW's CEO. "Cryoport's reputation for excellence in reproductive biologistics, paired with TMRW's cutting-edge specimen management technology and safety certifications, delivers unmatched security and peace of mind for transporting specimens in the fertility space."
Both TMRW and Cryoport are ISO-certified, underscoring their dedication to maintaining rigorous quality standards. TMRW is the only reproductive health storage provider with HIPAA-compliant, military-grade data security with SOC II and HITRUST certifications, along with cloud-based monitoring through Overwatch® and its proprietary, cloud-based ivfOS software for digitally managing specimens. Cryoport brings over a decade of experience in reproductive medicine biologistics including state-of-the-art tracking and visibility via its validated Cryoportal® Logistics Management Platform. Together, these certifications and advanced technologies will help to ensure that every aspect of specimen management, storage and transport adheres to the highest levels of safety, security and quality control.
"Cryoport is pleased to be joining forces with TMRW Life Sciences , a leader in fertility technology, to provide clinics with secure and seamless transport experiences for specimens," added Cryoport Systems President and CEO, Dr. Mark Sawicki. "Our organizations share a mutual focus on derisking processes, innovation and quality. By combining forces and bringing our solutions and expertise to this endeavor, we can offer unmatched end-to-end solutions for the safe transport, management and storage of frozen eggs, embryos and sperm."
By leveraging TMRW's digital specimen management system and Cryoport's expertise in temperature-controlled logistics for the life sciences, fertility clinics, and patients can be confident in the data integrity and safety of their specimens from clinic to transport to storage.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), ), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Our corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates
About TMRW Life Sciences
Founded in 2018, TMRW Life Sciences, Inc., is a fertility technology company digitizing the IVF lab starting with the world's first automated platform for the safe management and storage of frozen sperm, eggs and embryos. For the first time, frozen specimens can be digitally identified and tracked, safely managed with automated robotics, and remotely monitored around the clock. TMRW's next-generation technology platforms set a new standard of care, reducing potential points of failure by
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the partnership with TMRW Life Sciences, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tmrw-life-sciences-and-cryoport-systems-form-strategic-partnership-to-elevate-standards-for-frozen-egg-embryo-and-sperm-offsite-storage-and-biologistics-302281490.html
SOURCE Cryoport, Inc.
FAQ
What is the purpose of the partnership between TMRW Life Sciences and Cryoport Systems (CYRX)?
What certifications do TMRW Life Sciences and Cryoport Systems (CYRX) have?
How will the partnership between TMRW Life Sciences and Cryoport Systems (CYRX) benefit fertility clinics?
What technologies are offered by TMRW Life Sciences and Cryoport Systems (CYRX) in this partnership?
